Private Equity and Antitrust Enforcement: New HSR Rule Compliance; Trump Administration’s Priorities
A live 90-minute premium CLE video webinar with interactive Q&A
This CLE webinar will discuss the new Hart-Scott-Rodino (HSR) premerger notification requirements and their implications on private equity firms and sponsors. The panel will review the expanded data and disclosure requirements including disclosures of minority equity holders and certain limited partners, the enhanced business and competition documents, and regulators' increased scrutiny of prior acquisitions. The panel will also highlight the antitrust priorities and agenda for private equity under the new Trump administration.
Outline
- Overview: new HSR rules and antitrust priorities of the Trump administration
- Key rule changes that directly impact private equity firms and sponsors
- Expanded data and disclosure requirements
- Enhanced business and competition documents
- Disclosures concerning prior acquisitions
- Ownership disclosures
- Other generally applicable provisions that increase the reporting requirements for private equity firms
- Measures private equity sponsors must take to ensure compliance with the new rules
- Trump administration's antitrust priorities and their impact on private equity
- Practitioner pointers and key takeaways
Benefits
The panel will address these and other key issues:
- What provisions of the new rules directly impact private equity firms?
- What are the implications of the new rules on deals and transactions?
- What actions must private equity firms take to ensure compliance with the new rules?
- What are the Trump administration's antitrust priorities and how will they impact private equity?
Faculty

Jesse Solomon
Partner
Davis Polk & Wardwell
Mr. Solomon routinely represents clients in antitrust investigations of complex, high-profile transactions and in... | Read More
Mr. Solomon routinely represents clients in antitrust investigations of complex, high-profile transactions and in non-merger conduct investigations before the Federal Trade Commission and the U.S. Department of Justice. In his M&A advisory practice, Mr. Solomon develops global strategies for obtaining competition clearance of transactions across international jurisdictions, with particular experience in transactions in the pharmaceuticals, healthcare, technology, chemicals and consumer products industries. He has been the lead partner for clients in some of the largest and most challenging antitrust investigations in recent history.
CloseEarly Discount (through 05/23/25)